Overrepresentation of effector T cells at presentation may affect clinical response to lenalidomide and obinutuzumab treatment. (A) CD4 and CD8 EM T-cell percentages at baseline for responder (R) and nonresponder (NR) patients, as assessed by computed tomography scanning after 3 cycles of treatment. *P < .05, Mann-Whitney U test. (B) Forest plot of hazard ratios (HRs) based on PFS. The forest plot indicates the HRs with 95% confidence intervals and P values according to each variable.